TCEAL1

Across TCGA pan-cancer cohorts, TCEAL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TCEAL1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCEAL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TCEAL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, HNSC, and GBM are the cancer types where TCEAL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.564	0.213	<.001	48	view →
HNSC	DFS	Median	All	0.303	0.886	.007	41	view →
GBM	OS	Quartile	All	0.626	0.365	.002	15	view →
UCEC	OS	Tertile	II,III,IV	0.356	1.000	.003	12	view →
CCRCC	DFS	Median	All	0.611	0.856	.006	7	view →
LUAD	OS	Median	II,III,IV	0.893	0.457	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TCEAL1–PDAC (DFS)

Open the PDAC breakdown →